This Is Too Hot For Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, BCLI falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.74 and fluctuated between $0.7500 as its day high and $0.5900 as its day low. The current market capitalization of Brainstorm Cell Therapeutics, Inc. is $36.24M. A total of 1.44 million shares were traded on the day, compared to an average of 972.38K shares.

In the most recent transaction, Lindborg Stacy bought 11,500 shares of BCLI for 1.77 per share on Sep 01 ’23. After the transaction, the Co-Chief Executive Officer now owns 181,500 company shares.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BCLI has a high of $3.46 and a low of $0.13.

As of this writing, BCLI has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0. The company reported an EPS of -$0.14 in the last quarter, which was 12.50% higher than expectations of -$0.16.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BCLI’s latest balance sheet shows that the firm has $22.09M in Cash & Short Term Investments as of fiscal 2021. There were $5.08M in debt and $6.32M in liabilities at the time. Its Book Value Per Share was -$0.08, while its Total Shareholder’s Equity was $19.34M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCLI is Buy with a score of 3.00.

Most Popular

Related Posts